04.20.26 -- Why A Cell Therapy CEO Waited Until Phase III To Outsource

Developer choices in manufacturing strategy are as vital as the therapies themselves. Learn how to optimize production pathways to accelerate innovation and bridge the gap from promise to patient.

Discover how gene editing and HLA-F technologies are redefining allogeneic therapy. Explore these strategies to improve scalability and efficacy in next-generation cell development.

Animal‑free raw materials offer adjustable attributes, controlled manufacturing, and consistent nutrient profiles, ensuring reliable performance and customizable solutions across multiple production processes.

Scaling viral vector production requires precision. Gain insights into optimizing processes to ensure consistent titers and activity for more robust and reliable gene therapy development.

Next-generation sequencing is essential for rapid DNA/RNA analysis. Understand how this technology drives process optimization, impurity detection, and cost-effective therapy development.

Achieving sustainability in rare disease drug development requires a multifaceted approach. This roundtable discussion examines the essential strategies to build a sustainable, long-term pathway.

Observe how these streamlined, scalable platforms are transforming viral vector manufacturing to accelerate the delivery of cell and gene therapies to patients.